Vigil Neuroscience, Inc..
VIGL.US | Research and experimental development on natural sciences and engineering
Vigil Neuroscience, Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company's pipeline includes monoclonal antibody programs targeting microglia, the brain's immune cells, to address diseases like Alzheimer's disease and other rare microgliopathie...Show More
Better Health for All
20
Vigil Neuroscience's core business is dedicated to developing therapies for severe neurodegenerative diseases like Alzheimer's and ALSP, which have high unmet medical needs.
1
This indicates that 100% of its portfolio aims for revolutionary health benefits. The company is a clinical-stage biotechnology firm
2
and reported a net loss of $22.4 million in Q1 2025,
3
confirming it has no revenue from products, thus no revenue from products with direct health impacts. Its drug candidates, VG-3927 and iluzanebart, have demonstrated favorable safety and tolerability profiles in early-stage clinical trials, with no serious adverse events reported for VG-3927 and all related adverse events being mild or moderate and self-resolving.
4
The company's entire R&D budget is dedicated to health improvement, with R&D expenses for Q1 2025 at $16.5 million, up from $14.3 million in Q1 2024.
5
Clinical trials for VG-3927 included 115 participants, with 34 participants aged 55 and older, and also included a single-dose cohort of Alzheimer's patients, some with genetic risk factors, demonstrating good diversity and inclusion.
6
However, the company disclosed that its Phase 2 IGNITE trial for iluzanebart in ALSP patients showed no beneficial effects on biomarker or clinical efficacy endpoints, leading to the discontinuation of the long-term extension study, which represents a significant negative outcome for a core product.
7
Fair Money & Economic Opportunity
0
No evidence available to assess Vigil Neuroscience, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
Vigil Neuroscience has no employees covered by collective bargaining agreements or represented by labor organizations, and there are no labor organizations seeking to represent employees.
1
Since January 10, 2022, the company has not had any allegations of sexual harassment, sexual misconduct, or other unlawful harassment or discrimination, nor any material legal proceedings related to employment.
2
There are no unfair labor practice complaints pending or threatened against the company.
3
For a period of one year following a merger, continuing employees will receive base salary, target annual cash incentive compensation, and broad-based employee benefits that are no less favorable than prior to the merger.
4
The company provides 75-80% health insurance coverage for its workforce.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Vigil Neuroscience, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
50
Vigil Neuroscience, Inc. has a 'None' controversy level according to Sustainalytics data, indicating no recorded controversies.
1
Kind to Animals
-20
Vigil Neuroscience, Inc. uses animals for pre-clinical studies to examine the safety profile of their medications, as explicitly stated on their website.
1
No data is provided regarding the company's use of alternative testing methods, humane certifications for animal operations, ethical input substitution, supplier audits, cage-free sourcing, animal testing volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free research collaboration, or public policy engagement.
2
No War, No Weapons
0
The provided article from OpenSecrets.org states that Vigil Neuro had $0 in lobbying spending for the Pharmaceuticals/Health Products industry for the years 2022, 2023, and 2024.
1
This information does not provide specific evidence for any of the KPIs related to the 'No War, No Weapons' value, as it does not address revenue from arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, or lobbying specifically opposing arms control. No other relevant facts were found in the article for the defined KPIs.
Planet-Friendly Business
0
No specific quantitative data or verifiable actions related to planet-friendly business practices were found across the provided articles. While one article mentions the company was awarded the highest level 'Green' certificate from the My Green Lab Certification program, no details or quantitative metrics about this certification are provided to assess its impact against the rubric's KPIs, such as the percentage of facilities covered or specific environmental outcomes.
1
Respect for Cultures & Communities
0
No evidence available to assess Vigil Neuroscience, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-10
Vigil Neuroscience has not identified any cybersecurity incidents or threats that have materially affected the company, covering at least the past three years.
1
The company's audit committee oversees a cybersecurity risk management program that includes ongoing monitoring for potential critical risks and leverages a managed security service provider.
2
The Information Security Officer (ISO), with over 20 years of experience, reports periodically to the audit committee and the full board of directors.
3
The company engages third parties for periodic penetration testing and other vulnerability analyses, and has a process for the ISO to report relevant findings to management.
4
However, critical vulnerabilities are patched within 21-30 days on average. The company complies with the General Data Protection Regulation (GDPR), the UK Data Protection Act 2018, and CCPA.
5
Its privacy policy details user rights to access, rectify, erase, restrict processing, object to processing, and data portability.
6
Zero Waste & Sustainable Products
0
No specific, quantifiable evidence was found in the provided articles for any of the 'Zero Waste & Sustainable Products' KPIs. Information regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification percentage, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was not explicitly stated.
1